MedPath

Excessive Supraventricular Activity and Atrial Fibrillation

Recruiting
Conditions
Atrial Fibrillation
Supraventricular Beat, Premature
Premature Supraventricular Beats
Premature Atrial Complex
Extrasystole, Atrial
Atrial Flutter
Interventions
Diagnostic Test: Holter recording
Diagnostic Test: Echocardiography (Echo)
Diagnostic Test: Blood sample
Diagnostic Test: 24 hour ambulatory blood pressure monitoring And Arteriograph
Registration Number
NCT04593498
Lead Sponsor
Karolinska Institutet
Brief Summary

The aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (ESVEA) on Holter recording should be subjected to prolonged screening with Event loop recorder in order to detect previously undiagnosed Atrial fibrillation / flutter. Other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in ESVEA and control group as well as progression of atrial cardiomyopathy in ESVEA patients.

Detailed Description

Excessive supraventricular ectopic activities (ESVEA) are a common finding on long-term ECG recordings and have a connection to atrial cardiomyopathy, incident AF, stroke and mortality.

Holter recording from 2022 preformed at Danderyd hospital will be screened in order to identify 125 recordings with ESVEA, defined as at least 30 atrial ectopic beats/hour or a supraventricular run of at least 20 consecutive beats. Participants fulfilling eligibility criteria will be offered prolonged AF screening with continuous holter recording during 14 days. A matched control group (125 participants) without ESVEA will also be screened using same method.

Cardiovascular data from medical records will be collected in order to obtain information regarding co-morbidities and being able to assess CHA2DS2-VASC score. Participants will be asked to fill in a questionnaire.

Samples of blood will be collected at index time, after 21± 3 months for further analysis with the aim of identifying biomarkers for atrial fibrillation. During these two time periods echocardiography, 24 hour ambulatory blood pressure monitoring and assessment af artery stiffness with Arteriograph will also be preformed.

The study population will after 21± 3 months be subjected to renewed screening with Holter in order to examine the persistence of excessive supraventricular activity.

Four years after the completion of screening visits, data from patient records and information thorough telephone interview and/or data from Swedish Patient Register, Swedish Dispensed Drug Register will be collected

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
250
Inclusion Criteria

Patients with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats on a Holter recording.

Read More
Exclusion Criteria

Age < 70 years, >89 years Atrial fibrillation / flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Non-ESVEAEchocardiography (Echo)Participants not meeting inclusion criteria
ESVEAHolter recordingESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
ESVEAEchocardiography (Echo)ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
ESVEA24 hour ambulatory blood pressure monitoring And ArteriographESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
Non-ESVEA24 hour ambulatory blood pressure monitoring And ArteriographParticipants not meeting inclusion criteria
ESVEABlood sampleESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
Non-ESVEAHolter recordingParticipants not meeting inclusion criteria
Non-ESVEABlood sampleParticipants not meeting inclusion criteria
Primary Outcome Measures
NameTimeMethod
atrial fibrillation yield in extended ECG screening among patients with ESVEA on Holter recording as compared to patients without ESVEA.10-14 days

Proportion of patients with at least one episode of atrial fibrillation with a duration of at least 30 seconds among patients with ESVEA on Holter recording as compared to patients without ESVEA.

Secondary Outcome Measures
NameTimeMethod
the clinical development of atrial fibrillation subtype in patients diagnosed with atrial fibrillation.2 years

Presence of paroxysmal or permanent atrial fibrillation on follow-up.

Temporal development of ESVEA and atrial cardiomyopathy on repeated Holter recordings.2 years

Comparison of burden of supraventricular extrasystolic beats and number of episodes and duration of longest episode of supraventricular tachycardia.

Temporal development of several blood biomarkers with a possible relation to atrial cardiomyopathy in patients with and without ESVEA.2 years

Explorative sequential analysis of several blood biomarkers using PEA:

Artrial stiffness in relation to ESVEA and/or AF.2 yeras

Comparison of artrial stiffness and blood pressure

association between plasma biomarkers and the development of atrial fibrillation in patients with ESVEA.2 years

Comparison of biomarker profile in patients diagnosed with atrial fibrillation and patients not diagnosed with atrial fibrillation.

Association between ESVEA, atrial fibrillation and other relevant comorbidities such as stroke, heart failure and major bleeding as well as mortality.4 years or longer

Long-term data on incident stroke, heart failure, major bleedning and mortality compared between ESVEA- and non-ESVEA groups.

echocardiographic parameters in relation to ESVEA and/or AF.2 years

Comparison of echocardiographic parameters with focus on atrial dimension and function compared between ESVEA and non-ESVEA group.

Trial Locations

Locations (1)

Danderyd Hospital

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath